AlloVir Stock (NASDAQ:ALVR)
Previous Close
$9.42
52W Range
$7.96 - $24.15
50D Avg
$9.73
200D Avg
$14.55
Market Cap
$49.48M
Avg Vol (3M)
$22.94K
Beta
0.62
Div Yield
-
ALVR Company Profile
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
ALVR Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| KRON | Kronos Bio, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| CRNX | Crinetics Pharmaceuticals, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| FDMT | 4D Molecular Therapeutics, Inc. |
| STOK | Stoke Therapeutics, Inc. |
| ANAB | AnaptysBio, Inc. |
| AGIO | Agios Pharmaceuticals, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| MRUS | Merus N.V. |
| INBX | Inhibrx Biosciences, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |